PMID- 12133317
OWN - NLM
STAT- MEDLINE
DCOM- 20020913
LR  - 20131121
IS  - 1001-0939 (Print)
IS  - 1001-0939 (Linking)
VI  - 25
IP  - 5
DP  - 2002 May
TI  - [Losartan in the rat model of bleomycin-induced pulmonary fibrosis and its impact 
      on the expression of monocyte chemoattractant protein-1 and basic fibroblast 
      growth factor].
PG  - 268-72
AB  - OBJECTIVE: To study the effect of losartan on bleomycin-induced pulmonary 
      fibrosis in rats and its possible mechanism. METHODS: Pulmonary fibrosis was 
      induced in Wistar rats by intratracheal instillation of bleomycin. Then the rats 
      received daily losartan 10 mg/kg (group L), prednisone 20 mg/kg (group P), or 
      normal saline (group B) orally. Normal controls received normal saline both 
      intratracheally and orally. Six rats in each group were sacrificed 3, 7, 14, 28 
      and 56 days after intratracheal instillation. Histological changes of the lungs 
      were evaluated by HE stain, Masson's trichrome stain and sirius red stain. 
      Collagen content of the lung tissue was assessed by hydroxyproline concentration. 
      The mRNAs of monocyte chemoattractant protein-1 (MCP-1) and basic fibroblast 
      growth factor (bFGF) were detected by reverse transcription-polymerase chain 
      reaction (RT-PCR). Lung expression of MCP-1 and bFGF proteins was assessed by 
      immunohistochemistry and the level of MCP-1 protein was further measured by 
      ELISA. RESULTS: Pulmonary fibrosis of group L and group P was improved as 
      compared with that of group B. Hydroxyproline concentrations of group L and group 
      P were lower than that of group B. Protein expression of MCP-1 and bFGF in group 
      L was lower than that in group B. CONCLUSION: Losartan alleviates 
      bleomycin-induced pulmonary fibrosis in rats. Inhibiting the expressions of MCP-1 
      and bFGF in lung tissues may be one of the mechanisms.
FAU - Fang, Xiangqun
AU  - Fang X
AD  - Department of Respiratory Disease, Peking Union Medical College Hospital, Peking 
      Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.
FAU - Zhu, Yuanjue
AU  - Zhu Y
FAU - Hu, Xiaoling
AU  - Hu X
FAU - Liu, Yongjian
AU  - Liu Y
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Jie He He Hu Xi Za Zhi
JT  - Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal 
      of tuberculosis and respiratory diseases
JID - 8712226
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Chemokine CCL2)
RN  - 0 (RNA, Messenger)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 11056-06-7 (Bleomycin)
RN  - 9007-34-5 (Collagen)
RN  - JMS50MPO89 (Losartan)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents/administration & dosage/therapeutic use
MH  - Antihypertensive Agents/administration & dosage/*therapeutic use
MH  - Bleomycin
MH  - Chemokine CCL2/*genetics/metabolism
MH  - Collagen/drug effects/metabolism
MH  - Drug Therapy, Combination
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fibroblast Growth Factor 2/*genetics/metabolism
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Losartan/administration & dosage/*therapeutic use
MH  - Lung/drug effects/metabolism/pathology
MH  - Male
MH  - Prednisone/administration & dosage/therapeutic use
MH  - Pulmonary Fibrosis/chemically induced/*drug therapy/genetics
MH  - RNA, Messenger/drug effects/genetics/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Treatment Outcome
EDAT- 2002/07/23 10:00
MHDA- 2002/09/14 10:01
CRDT- 2002/07/23 10:00
PHST- 2002/07/23 10:00 [pubmed]
PHST- 2002/09/14 10:01 [medline]
PHST- 2002/07/23 10:00 [entrez]
PST - ppublish
SO  - Zhonghua Jie He He Hu Xi Za Zhi. 2002 May;25(5):268-72.